Clinical challenges exist in reducing prostate cancer (PCa) disparities. The RNA splicing
landscape of PCa across racial populations has not been fully explored as a potential …

Men with metastatic prostate cancer who are treated with androgen deprivation therapies
(ADT) usually relapse within 2 to 3 years with disease that is termed castration-resistant …

The androgen receptor (AR) is a central driver of aggressive prostate cancer. After initial
treatment with androgen receptor signaling inhibitors (ARSi), reactivation of AR signaling …

The incidence and mortality rates of prostate cancer (PCa) are higher in African American
(AA) compared to Caucasian American (CA) men. To elucidate the molecular mechanisms …

Alternative splicing (AS) is a crucial step in gene expression. It is subject to intricate
regulation, and its deregulation in cancer can lead to a wide array of neoplastic phenotypes …

The role of dysregulation of mRNA alternative splicing (AS) in the development and
progression of solid tumors remains to be defined. Here we describe the first comprehensive …

Androgen receptor (AR), is a transcription factor and a member of a hormone receptor
superfamily. AR plays a vital role in the progression of prostate cancer and is a crucial target …

Men of predominantly African Ancestry (AA) have higher prostate cancer (CaP) incidence
and worse survival than men of predominantly European Ancestry (EA). While …

There is significant need to identify novel prostate cancer drug targets because current
hormone therapies eventually fail, leading to a drug-resistant and fatal disease termed …

Background African ancestry is a significant risk factor for advanced prostate cancer (PCa).
Mortality rates in sub-Saharan Africa are 2.5-fold greater than global averages. However, the …